Finance

Beta
Lists
CSPCY:OTCMKTS
CSPC Pharmaceuticals Group ADR
US$ ३.६४
-४.४६%
(-०.१७) 1D
जुन ३, १६:००:०० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CSPCY...
Open
US$ ३.७७
High
US$ ३.७७
Low
US$ ३.६४
Mkt. cap
८३.५४ अरब
Avg. vol.
२.१४ हजार
Volume
१.१२ हजार
52-wk high
US$ ५.८३
52-wk low
US$ ३.४५
Beta
०.३८
Shares outstanding
२.८८ अरब
No. of employees
२० हजार
Open
US$ ३.७७
High
US$ ३.७७
Low
US$ ३.६४
Mkt. cap
८३.५४ अरब
Avg. vol.
२.१४ हजार
Volume
१.१२ हजार
52-wk high
US$ ५.८३
52-wk low
US$ ३.४५
Beta
०.३८
Shares outstanding
२.८८ अरब
No. of employees
२० हजार
News stories
From sources across the web
Profile
CSPC Pharmaceutical Group researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province. CSPC produces both active pharmaceutical ingredient and formulations. API products include penicillin, cefalosporins, synthetic vitamins, caffeine and ranitidine. Formulations include antibiotics, butylphthalide and analgesics, in addition to nearly 1,000 other products. CSPC's 15,000 employees are divided among more than ten subsidiaries, including CSPC Zhongrun, Weisheng, Zhongnuo and NBP. CSPC Pharma's total assets are valued above RMB 8 billion. In 2007, CSPC Pharma achieved sales of RMB 8 billion and net income of RMB 485 million. Direct exports of US$300 million ranked CSPC first among China's pharmaceutical enterprises. One subsidiary, China Pharmaceutical Group Co., Ltd is based in Hong Kong. It is listed on the Hang Seng China-Affiliated Corporations Index. In 2003 and 2004, China Pharma was listed as one of 100 excellent listed companies with turnover less than $1 billion. CSPC Pharma is recognized as one of China's "500 Most Valuable Chinese Brands" and "Top 500 Chinese Enterprises." Wikipedia
About CSPC Pharmaceuticals Group ADR
CEOZhang Cuilong
Employees१९.७ हजार
Founded१९९२
Headquarters-
Sector-
Websitecspc.com.hk
Previous reportsAll values in HKD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
Revenue
६.२६ अरब
६.६२ अरब
६.११ अरब
६.४७ अरब
Cost of goods sold
२.२५ अरब
२.२८ अरब
२.११ अरब
२.२० अरब
Cost of revenue
२.२५ अरब
२.२८ अरब
२.११ अरब
२.२० अरब
Research and development expenses
१.३८ अरब
१.५० अरब
१.६२ अरब
१.४० अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१.५६ अरब
१.९७ अरब
१.८७ अरब
१.८९ अरब
Operating expense
२.९४ अरब
३.४७ अरब
३.४९ अरब
३.२९ अरब
Total operating expenses
५.२० अरब
५.७५ अरब
५.६० अरब
५.४९ अरब
Operating income
१.०६ अरब
८६.९६ करोड
५१.४७ करोड
९७.३८ करोड
Other non operating income
३५.९९ लाख
६४.५५ करोड
-४७.०४ करोड
१८.१८ करोड
EBT including unusual items
१.३२ अरब
१.१८ अरब
५०.५६ करोड
१.१३ अरब
EBT excluding unusual items
१.१४ अरब
१.३७ अरब
१८.६६ करोड
१.१३ अरब
Income tax expense
२४.२४ करोड
२२.२५ करोड
१६.५६ करोड
२४.३२ करोड
Effective tax rate
१८.३४%
१८.७८%
३२.७६%
२१.४६%
Other operating expenses
-
-
-
-
Net income
१.०७ अरब
९६.३५ करोड
३७.०७ करोड
८५.९८ करोड
Net profit margin
१७.०९%
१४.५६%
६.०६%
१३.३०%
Earnings per share
-
-
-
-
Interest and investment income
९.५० करोड
-
१९.५९ करोड
-
Interest expense
-१.४९ करोड
-१०.५२ करोड
-६७.५७ लाख
-१.१० करोड
Net interest expenses
८.०१ करोड
-१०.५२ करोड
१८.९१ करोड
-१.१० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
१.३६ अरब
१.१४ अरब
८०.२१ करोड
१.२६ अरब
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer